Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-115 dose-response study in progressive fibrosing interstitial lung disease
jRCT2051210050Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pamufetinib in Chronic fibrosing interstitial lung disease (PF-ILD) (3 cohorts), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: 26-week rate of decline in FVC. Started Oct 2021; status: completed.
02
Drugs
pamufetinib
03
Conditions
Chronic fibrosing interstitial lung disease (PF-ILD)
Beyond the preview
Go deeper on jRCT2051210050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210050.